Since the introduction of chromosomal banding techniques in the early 1970's, numerous tumors have been associated with specific chromosomal defects. Prezygotic chromosomal deletions have been causally related to two specific childhood tumors (retinoblastoma and Wilm's), while a large number of hematopoietic neoplasms have been associated with site-specific translocations or complete or partial monosomy. Less is known about the chromosome abnormalities of solid tumors because it has been technically difficult to obtain chromosome preparations from them, but there is evidence of specific changes in solid tumors as well. Thus, we are confronted with many striking examples of the relationship between chromosome structure. molecular regulation. gene expression and oncogenesis. To gain further insight into this relationship, the highest levels of sophistication in chromosomal, molecular and gene mapping techniques are required. In recent years, geneticists have employed the procedure of somatic cell hybridization for studies of gene control and gene mapping. Cells from two species are fused to form a single cell, and in the process chromosomes are lost. Clones developed from a hybrid retain a set of chromosomes characteristic of the clone, and one can correlate gene expression or presence of a specific DNA sequence with the presence or absence of that particular chromosome in a panel of hybrid clones. Numerous genes have been mapped using this method, and success relies heavily upon cytogenetic evaluation of the hybrid clones. Of all the gene mapping procedures, however, the one with the greatest potential is in situ hybridization. With this method, it is now possible to directly map any DNA sequence, even if it does not code for an identifiable gene product. Therefore, it is not a coincidence that the elements which contribute to this confluence of cytogenetics and molecular biology were put in place in the cytogenetics laboratory at The Children's Hospital of Philadelphia. The ability to dissect the chromosome at both the cytogenetic and molecular levels will rely upon services offered by the Cytogenetics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA047983-01
Application #
3821209
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30
Biegel, J A; Nycum, L M; Valentine, V et al. (1995) Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization. Genes Chromosomes Cancer 12:186-92
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22

Showing the most recent 10 out of 75 publications